Vascular and renal actions of brain natriuretic peptide in man: Physiology and pharmacology

Fundamental and Clinical Pharmacology

Volumn 19, Issue 4, 2005, Pages 411-419

  Houben, Alphons J H M ^a   Van Der Zander, Kim ^a   De Leeuw, Peter W ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brain natriuretic peptide; Hemodynamics; Physiology; Renal; Vascular

Indexed keywords

ALDOSTERONE SYNTHASE; ANGIOTENSIN; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN;

BLOOD PRESSURE; DIURESIS; DRUG EFFECT; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEART AFTERLOAD; HEART OUTPUT; HEART PRELOAD; HEART RATE; HEMODYNAMICS; HUMAN; KIDNEY BLOOD FLOW; MEAN ARTERIAL PRESSURE; NATRIURESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; HEART RATE; HUMANS; KIDNEY; NATRIURETIC PEPTIDE, BRAIN; VASODILATION;

EID: 22344444450     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2005.00336.x     Document Type: Review

References (87)

1. de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. (1981) 28 89-94.
2. Kangawa K., Fukuda A., Kubota I., Hayashi Y., Matsuo H. Identification in rat atrial tissue of multiple forms of natriuretic polypeptides of about 3000 daltons. Biochem. Biophys. Res. Commun. (1984) 121 585-591.
3. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature (1988) 332 78-81.
4. Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. (1990) 168 863-870.
5. Schweitz H., Vigne P., Moinier D., Frelin C., Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem. (1992) 267 13928-13932.
6. Latini R., Masson S., de Angelis N., Anand I. Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. J. Card. Fail. (2002) 8 288-299.
7. Kambayashi Y., Nakao K., Mukoyama M. et al. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett. (1990) 259 341-345.
8. Mukoyama M., Nakao K., Hosoda K. et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J. Clin. Invest. (1991) 87 1402-1412.
9. Ogawa Y., Nakao K., Mukoyama M. et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ. Res. (1991) 69 491-500.
10. Hosoda K., Nakao K., Mukoyama M. et al. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension (1991) 17 1152-1155.
11. Kohno M., Horio T., Yokokawa K. et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am. J. Med. (1992) 92 29-34.
12. Kinnunen P., Vuolteenaho O., Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology (1993) 132 1961-1970.
13. Bianciotti L.G., de Bold A.J. Modulation of cardiac natriuretic peptide gene expression following endothelin type A receptor blockade in renovascular hypertension. Cardiovasc. Res. (2001) 49 808-816.
14. Ogawa T., Linz W., Stevenson M. et al. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation (1996) 93 2059-2067.
15. Bruneau B.C., Piazza L.A., de Bold A.J. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am. J. Physiol. (1997) 273 H2678-H2686.
16. Bruneau B.G., Piazza L.A., de Bold A.J. Alpha 1-adrenergic stimulation of isolated rat atria results in discoordinate increases in natriuretic peptide secretion and gene expression and enhances Egr-1 and c-Myc expression. Endocrinology (1996) 137 137-143.
17. Clerico A., Del Ry S., Maffei S., Prontera C., Emdin M., Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin. Chem. Lab. Med. (2002) 40 371-377.
18. Jensen K.T., Carstens J., Pedersen E.B. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am. J. Physiol. (1998) 274 F63-F72.
19. Jensen K.T., Eiskjaer H., Carstens J., Pedersen E.B. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin. Sci. (Lond) (1999) 96 5-15.
20. Lazzeri C., La Villa G., Bisi G. et al. Cardiovascular function during brain natriuretic peptide infusion in man. Cardiology (1995) 86 396-401.
21. La Villa G., Stefani L., Lazzeri C. et al. Acute effects of physiological increments of brain natriuretic peptide in humans. Hypertension (1995) 26 628-633.
22. La Villa G., Fronzaroli C., Lazzeri C. et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J. Clin. Endocrinol. Metab. (1994) 78 1166-1171.
23. Holmes S.J., Espiner E.A., Richards A.M., Yandle T.G., Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. (1993) 76 91-96.
24. Yoshimura M., Yasue H., Morita E. et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation (1991) 84 1581-1588.
25. McGregor A., Richards M., Espiner E., Yandle T., Ikram H. Brain natriuretic peptide administered to man: actions and metabolism. J. Clin. Endocrinol. Metab. (1990) 70 1103-1107.
26. Cheung B.M., Dickerson J.E., Ashby M.J., Brown M.J., Brown J. Effects of physiological increments in human alpha-atrial natriuretic peptide and human brain natriuretic peptide in normal male subjects. Clin. Sci. (Lond) (1994) 86 723-730.
27. van der Zander K., Houben A.J., Hofstra L., Kroon A.A., de Leeuw P.W. Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am. J. Physiol. Heart Circ. Physiol. (2003) 285 H1206-H1212.
28. Cowie M.R., Jourdain P., Maisel A. et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur. Heart J. (2003) 24 1710-1718.
29. Lang C.C., Choy A.M., Turner K., Tobin R., Coutie W., Struthers A.D. The effect of intravenous saline loading on plasma levels of brain natriuretic peptide in man. J. Hypertens. (1993) 11 737-741.
30. Lang C.C., Coutie W.J., Khong T.K., Choy A.M., Struthers A.D. Dietary sodium loading increases plasma brain natriuretic peptide levels in man. J. Hypertens. (1991) 9 779-782.
31. La Villa G., Vena S., Conti A. et al. Plasma levels of brain natriuretic peptide in healthy subjects and patients with essential hypertension: response to posture. Clin. Sci. (Lond) (1993) 85 411-416.
32. Koller K.J., Goeddel D.V. Molecular biology of the natriuretic peptides and their receptors. Circulation (1992) 86 1081-1088.
33. Nazario B., Hu R.M., Pedram A., Prins B., Levin E.R. Atrial and brain natriuretic peptides stimulate the production and secretion of C-type natriuretic peptide from bovine aortic endothelial cells. J. Clin. Invest. (1995) 95 1151-1157.
34. Moritoki H., Yoshikawa T., Hisayama T., Takeuchi S. Possible mechanisms of age-associated reduction of vascular relaxation caused by atrial natriuretic peptide. Eur. J. Pharmacol. (1992) 210 61-68.
35. Kubo M., Nakaya Y., Matsuoka S., Saito K., Kuroda Y. Atrial natriuretic factor and isosorbide dinitrate modulate the gating of ATP-sensitive K+ channels in cultured vascular smooth muscle cells. Circ. Res. (1994) 74 471-476.
36. Price J.M., Hellermann A. Inhibition of cGMP mediated relaxation in small rat coronary arteries by block of CA++ activated K+ channels. Life. Sci. (1997) 61 1185-1192.
37. Costa M.D., Bosc L.V., Majowicz M.P., Vidal N.A., Balaszczuk A.M., Arranz C.T. Atrial natriuretic peptide modifies arterial blood pressure through nitric oxide pathway in rats. Hypertension (2000) 35 1119-1123.
38. McLay J.S., Chatterjee P.K., Jardine A.G., Hawksworth G.M. Atrial natriuretic factor modulates nitric oxide production: an ANF-C receptor-mediated effect. J. Hypertens. (1995) 13 625-630.
39. Zellner C., Protter A.A., Ko E. et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am. J. Physiol. (1999) 276 H1049-H1057.
40. van der Zander K., Houben A.J., Kroon A.A., De Mey J.G., Smits P.A., de Leeuw P.W. Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man. J. Hypertens. (2002) 20 493-499.
41. Anand-Srivastava M.B. Atrial natriuretic peptide-C receptor and membrane signalling in hypertension. J. Hypertens. (1997) 15 815-826.
42. Yandle T.G., Richards A.M., Nicholls M.G., Cuneo R., Espiner E.A., Livesey J.H. Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci. (1986) 38 1827-1833.
43. Chabrier P.E., Roubert P., Lonchampt M.O., Plas P., Braquet P. Receptor regulation of atrial natriuretic factor. Blood Vessels (1990) 27 153-161.
44. Roubert P., Lonchampt M.O., Chabrier P.E., Plas P., Goulin J., Braquet P. Down-regulation of atrial natriuretic factor receptors and correlation with cGMP stimulation in rat cultured vascular smooth muscle cells. Biochem. Biophys. Res. Commun. (1987) 148 61-67.
45. Nakamura M., Arakawa N., Yoshida H., Makita S., Niinuma H., Hiramori K. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am. Heart J. (1998) 135 414-420.
46. Lazzeri C., Franchi F., Porciani C. et al. Systemic hemodynamics and renal function during brain natriuretic peptide infusion in patients with essential hypertension. Am. J. Hypertens. (1995) 8 799-807.
47. Richards A.M., Crozier I.G., Holmes S.J., Espiner E.A., Yandle T.G., Frampton C. Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension. J. Hypertens. (1993) 11 163-170.
48. Pidgeon G.B., Richards A.M., Nicholls M.G., Espiner E.A., Yandle T.G., Frampton C. Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Hypertension (1996) 27 906-913.
49. Lainchbury J.G., Richards A.M., Nicholls M.G. et al. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension (1997) 30 398-404.
50. Marcus L.S., Hart D., Packer M. et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation (1996) 94 3184-3189.
51. Yasue H., Yoshimura M. Natriuretic peptides in the treatment of heart failure. J. Card. Fail. (1996) 2 S277-S285.
52. Protter A.A., Wallace A.M., Ferraris V.A., Weishaar R.E. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am. J. Hypertens (1996) 9 432-436.
53. van der Zander K., Houben A.J., Kroon A.A., de Leeuw P.W. Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide. Cardiovasc. Res. (1999) 44 595-600.
54. Emori T., Hirata Y., Imai T., Eguchi S., Kanno K., Marumo F. Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. Endocrinology (1993) 133 2474-2480.
55. Gelfand R.A., Frank H.J., Levin E., Pedram A. Brain and atrial natriuretic peptides bind to common receptors in brain capillary endothelial cells. Am. J. Physiol. (1991) 261 E183-E189.
56. Ishibashi Y., Shimada T., Sakane T. et al. Contribution of endogenous nitric oxide to basal vasomotor tone of peripheral vessels and plasma B-type natriuretic peptide levels in patients with congestive heart failure. J. Am. Coll. Cardiol. (2000) 36 1605-1611.
57. Houben A.J., Krekels M.M., Schaper N.C., Fuss-Lejeune M.J., Rodriguez S.A., de Leeuw P.W. Microvascular effects of atrial natriuretic peptide (ANP) in man: studies during high and low salt diet. Cardiovasc. Res. (1998) 39 442-450.
58. Wijeyaratne C.N., Moult P.J. The effect of alpha human atrial natriuretic peptide on plasma volume and vascular permeability in normotensive subjects. J. Clin. Endocrinol. Metab. (1993) 76 343-346.
59. Colucci W.S., Elkayam U., Horton D.P. et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. (2000) 343 246-253.
60. Mills R.M., LeJemtel T.H., Horton D.P. et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J. Am. Coll. Cardiol. (1999) 34 155-162.
61. Wei C.M., Aarhus L.L., Miller V.M., Burnett J.C. Jr Action of C-type natriuretic peptide in isolated canine arteries and veins. Am. J. Physiol. (1993) 264 H71-H73.
62. Zhang L.M., Castresana M.R., McDonald M.H., Johnson J.H., Newman W.H. Response of human artery, vein, and cultured smooth muscle cells to atrial and C-type natriuretic peptides. Crit. Care Med. (1996) 24 306-310.
63. Lopez M.J., Garbers D.L., Kuhn M. The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling. J. Biol. Chem. (1997) 272 23064-23068.
64. Tolsa J.F., Gao Y., Sander F.C., Souici A.C., Moessinger A., Raj J.U. Differential responses of newborn pulmonary arteries and veins to atrial and C-type natriuretic peptides. Am. J. Physiol. Heart Circ. Physiol. (2002) 282 H273-H280.
65. Marin-Grez M., Fleming J.T., Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature (1986) 324 473-476.
66. Fried T.A., McCoy R.N., Osgood R.W., Stein J.H. Effect of atriopeptin II on determinants of glomerular filtration rate in the in vitro perfused dog glomerulus. Am. J. Physiol. (1986) 250 F1119-F1122.
67. Stockand J.D., Sansom S.C. Regulation of filtration rate by glomerular mesangial cells in health and diabetic renal disease. Am. J. Kidney Dis. (1997) 29 971-981.
68. Harris P.J., Thomas D., Morgan T.O. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature (1987) 326 697-698.
69. Dillingham M.A., Anderson R.J. Inhibition of vasopressin action by atrial natriuretic factor. Science (1986) 231 1572-1573.
70. Sonnenberg H., Honrath U., Chong C.K., Wilson D.R. Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am. J. Physiol. (1986) 250 F963-F966.
71. Zeidel M.L., Kikeri D., Silva P., Burrowes M., Brenner B.M. Atrial natriuretic peptides inhibit conductive sodium uptake by rabbit inner medullary collecting duct cells. J. Clin. Invest. (1988) 82 1067-1074.
72. Zeidel M.L. Regulation of collecting duct Na+ reabsorption by ANP 31-67. Clin. Exp. Pharmacol. Physiol. (1995) 22 121-124.
73. Light D.B., Schwiebert E.M., Karlson K.H., Stanton B.A. Atrial natriuretic peptide inhibits a cation channel in renal inner medullary collecting duct cells. Science (1989) 243 383-385.
74. van der Zander K., Houben A.J., Kroon A.A. et al. Does brain natriuretic peptide have a direct renal effect in human hypertensives? Hypertension (2003) 41 119-123.
75. De Feo M.L., La Villa G., Lazzeri C. et al. Urinary endothelin-1 excretion is enhanced by low-dose infusion of brain natriuretic peptide in normal humans. Hypertension (1997) 29 70-74.
76. Nitta K., Naruse M., Sanaka T. et al. Natriuretic and diuretic effects of endothelin in isolated perfused rat kidney. Endocrinol. Jpn (1989) 36 887-890.
77. Brunner-La Rocca H.P., Kaye D.M., Woods R.L., Hastings J., Esler M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J. Am. Coll. Cardiol. (2001) 37 1221-1227.
78. Blackburn R.E., Samson W.K., Fulton R.J., Stricker E.M., Verbalis J.G. Central oxytocin and ANP receptors mediate osmotic inhibition of salt appetite in rats. Am. J. Physiol. (1995) 269 R245-R251.
79. Burrell L.M., Lambert H.J., Baylis P.H. Effect of atrial natriuretic peptide on thirst and arginine vasopressin release in humans. Am. J. Physiol. (1991) 260 R475-R479.
80. Johnston C.I., Hodsman P.G., Kohzuki M., Casley D.J., Fabris B., Phillips P.A. Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists. Am. J. Med. (1989) 87 24S-28S.
81. Sigurdsson A., Swedberg K. The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. Am. Heart J. (1996) 132 229-234.
82. Rademaker M.T., Charles C.J., Espiner E.A., Frampton C.M., Nicholls M.G., Richards A.M. Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure. Clin. Sci. (Lond) (2004) 106 569-576.
83. Liang F., Gardner D.G. Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes. J. Biol. Chem. (1998) 273 14612-14619.
84. Ito T., Yoshimura M., Nakamura S. et al. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation (2003) 107 807-810.
85. Maisei A.S., Krishnaswamy P., Nowak R.M. et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. (2002) 347 161-167.
86. McGeoch G., Lainchbury J., Town G.I., Toop L., Espiner E., Richards A.M. Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur. J. Heart Fail. (2002) 4 479-483.
87. Vasan R.S., Benjamin E.J., Larson M.G. et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA (2002) 288 1252-1259.